Watch this webinar to find out how UpTempo Antibody addresses key challenges bringing antibody therapeutic programs to clinical trials.

In this article, find out how GPEx® cell line and pools can accelerate the timelines to First-in-human studies.

A poster presentation of how Catalent's GPEx® Lightning system enables faster development timelines, robust manufacturing processes, improved titers, and higher final yields.

This webinar explored the challenges of cell therapy manufacturing and introduced Catalent's UpTempo CAR-T Platform process as a solution.

Summary: In a recent presentation during the 2024 JP Morgan Healthcare Conference, Catalent’s Group President of Biologics Dave McErlane addresses the latest market drivers for Biologics and Sterile Injectables.

A poster presentation of a GMP manufacturing process for the creation of human iPSC for use in allogeneic cell therapy applications.

A poster presentation of the UpTempo CAR-T Manufacturing Platform.

Learn how Catalent took to a monoclonal antibody (mAb) from clinical to commercial phase under a highly compressed timeline.

The use of lipid nanoparticles (LNPs) as non-viral delivery tools for messenger RNA (mRNA) helps alleviate the otherwise poor pharmacokinetics (PK) and in vivo instability of mRNA. However, LNP formulation development and manufacturing remains complex and challenging.

The demand for mRNA-based vaccines and treatments has increased significantly, and the industry has been challenged to not only meet these needs, but also improve existing manufacturing processes and efficiencies.